100 results about "Solid Dose Form" patented technology

The present disclosure relates to a herbo-mineral kit for alleviating adverse effects of chemotherapy resulting into improved quality of life of patients. The herbo-mineral kit comprises a first container containing Padmakadi Ghrut (PDG) in a thick, viscous form; a second container containing Mouktikyukta Kamdudha Vati (MKD) in a solid dosage form; a third container containing Praval Pishti Vati (PPV) in a solid dosage form; and a fourth container containing Ananta vati in a solid dosage form. The herbo-mineral kit of the present disclosure can be used for alleviating adverse effects of chemotherapy such as nausea, vomiting, constipation, diarrhea, stomatitis, and skin discoloration in cancer treatment. Use of the herbo-mineral kit of the present disclosure may prove to be beneficial in all types of cancers and diseases for which chemotherapy is treatment of choice.

Enterically-coated solid dosage forms containing a pharmaceutical agent which includes bacteria and / or microbial extracellular vesicles (mEVs) are provided. Methods of treatment using such solid dosage forms are also provided.

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

The present disclosure is directed to oral dosage forms that comprise an antiviral nucleoside and one or more excipients, wherein the oral dosage form is a tablet. The antiviral nucleoside is selected from prodrugs of β-D-N(4)-hydroxycytidine (I) such as {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate): Compound (A), or a pharmaceutically acceptable salt, tautomer, or prodrug thereof.

The present disclosure relates to solid dose formulations for needle-free delivery comprising 0.01 to 60 (w / w) of one or more therapeutic agent and / or prophylactic agent; and 40.0% to 99.99% (w / w) of dextran. The invention further concerns methods of producing a solid dose formulation tablet and application its particular medical uses, in particular as a vaccine.

Disclosed herein are pharmaceutical oral solid dosage forms comprising a salt of liothyronin and a salt of levothyroxine, and methods of making and using the pharmaceutical oral solid dosage forms.

Described herein are dosage forms comprising the compound:wherein the dosage form can be a solid dosage form, a liquid dosage form, or a solid amorphous dispersion.

A polyalkylene oxide that can be suitably used to easily control a drug dissolution rate, a solid dosage form composition comprising the polyalkylene oxide and a method for producing the same, and a sustained-release dosage form composition are provided. The polyalkylene oxide has a polydispersity of 3 to 5, a gel strength of 22,500 Pa or more, and an erosion of 40 to 48%. The solid dosage form composition includes at least the polyalkylene oxide, an active component, and an excipient.

A device for dispensing solid dosage form comprises a chamber for storing solid dosage form, an outlet and a rotatable element comprising a disc. The disc comprises at least one aperture in a radially outer section of the disc and a surface configured to direct the solid dosage form in the chamber towards the radially outer section. The disc is configured to rotate to transport solid dosage form from the chamber to the outlet.

Provided herein are pharmaceutical formulations of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form. Also provided herein are methods of treating cancer comprising a pharmaceutical formulation of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form.

The present invention relates to formulations of elafibranor or a pharmaceutically acceptable salt or ester thereof; and uses thereof. In particular, the present invention relates to an oral solid dosage form comprising at least elafibranor or a pharmaceutically acceptable salt or ester thereof; a filler, a disintegrating agent and a binder.

This invention relates to pharmaceutical inclusion compounds, their preparation methods, and uses. Specifically, it provides a buggerfuran inclusion compound and its preparation method, wherein the inclusion compound comprises buggerfuran, cyclodextrin compounds, and optionally a high molecular weight polymer. This inclusion compound has a simple composition, high encapsulation efficiency, stability, and high safety, and can be used to prepare various liquid and solid dosage forms.

A solid dosage form for oral transmucosal delivery of an active pharmaceutical ingredient (API) is disclosed. Also provided are methods of treating a disease with the solid dosage form.

Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.

The present disclosure relates to oral dosage forms comprising an antiviral nucleoside and one or more excipients, wherein the oral dosage form is a tablet. The antiviral nucleoside is selected from a prodrug of beta-D-N (4)-hydroxycytidine (I), such as 2-methylpropionic acid {(2R, 3S, 4R, 5R)-3, 4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3, 4-dihydropyrimidin-1 (2H)-yl] oxacyclopentane-2-yl} methyl ester)-compound (A), or a pharmaceutically acceptable salt, tautomer or prodrug thereof. (I) (A)

The present invention relates to the use of co-processed excipients in the continuous production of solid dosage forms.

The present document describes a pharmaceutical excipient composition comprising a functionalized anionic polysaccharide having carboxyl groups complexed with an amino acid-divalent cation complex, monolithic solid dosage forms for dual rate release of an active pharmaceutical ingredient, comprising the pharmaceutical excipient composition and active pharmaceutical ingredients, as well as processes for preparing the pharmaceutical excipient composition.

Composition, in particular pharmaceutical composition, in the form of a fixed dosage (solid dosage form) for sucking and / or chewing, preferably for sucking, in particular lozenge, preferably for use in the prophylactic and / or therapeutic topical (local) treatment of inflammatory diseases of the mouth and throat, wherein the composition contains an effective, in particular pharmaceutically and / or therapeutically effective, amount of an active ingredient preferably suitable and / or effective for the topical (local) treatment of inflammatory diseases of the mouth and throat, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial and / or antiviral and / or antifungal properties, wherein the active ingredient is incorporated and / or embedded in a solid matrix, wherein the composition, in particular the solid dosage form and / or the matrix, releases the active ingredient upon topical (local) application and / or use, preferably by sucking and / or chewing, preferably by sucking, in the oral and pharyngeal cavity; wherein the active ingredient is octenidine, in particular in the form of a pharmaceutically compatible and / or physiologically acceptable salt or ester, preferably in the form of a pharmaceutically compatible and / or physiologically acceptable salt, particularly preferably octenidine dihydrochloride; and wherein the composition, in particular the solid dosage form and / or the matrix, furthermore and / or additionally contains at least one further ingredient (a) and / or (b), in particular (a) and (b), wherein the at least one further ingredient (a) and / or (b) is selected from the group of (a) Flavor modulators, in particular selected from the group of the following components (i), (ii) and / or (iii): (i) Bitter (taste) masking agents, in particular selected from the group consisting of bitter taste receptor antagonists, preferably 4-(2,2,3-trimethylcyclopentyl)butanoic acid, and saponins, preferably glycyrrhizic acid (glycyrrhizin) and its salts or esters and / or glycyrrhetinic acid (glycyrrhetin) and its salts or esters, complexing agents, in particular cyclodextrins, and combinations or mixtures thereof, (ii) Bitter substances, in particular coffee extract and / or tea extract and / or their respective bitter substances, preferably coffee extract and / or its bitter substances, (iii) preferably natural or nature-identical (aroma) oils and / or essential oils, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial, antifungal and / or antiviral properties, in particular selected from the group of anise oils, in particular star anise oil, peppermint oil, eucalyptus oil, lavender oil, tea tree oil, chamomile oil, clove oil, rosemary oil, caraway oil, cinnamon oil, sage oil and fennel oil, as well as combinations or mixtures thereof; in particular wherein the ingredient (a) and / or the flavor modulator comprises a combination of at least two different components (i), (ii) and / or (iii), preferably a combination of components (i), (ii) and (iii); (b) Acidulants, in particular saliva-stimulating and / or flavor-enhancing acidulants, preferably acidulants authorized under pharmaceutical and / or food law and / or acidulants authorized as pharmaceutical additives and / or food additives, in particular selected from the group of tartaric acid and its salts, in particular sodium tartrate, sodium potassium tartrate (Rochelle salt) and calcium tartrate, citric acid and its salts, metatartaric acid, fumaric acid, ascorbic acid, phosphoric acid and its salts, stannous chloride, in particular tin(II) chloride, malic acid, lactic acid, adipic acid, succinic acid and other pharmaceutically compatible and / or physiologically acceptable organic acids and their salts, as well as their combinations or mixtures.

The present disclosure provides a solid dosage form for customized release of a nutraceutical, wherein the solid dosage form comprises a plurality of tablets in a single capsule, wherein at least one tablet of the plurality comprises a dose of the nutraceutical. Also provided herein are methods for improving bioavailability of a nutraceutical in a subject by administering a solid dosage form described herein.

A solid dosage form for injection and a method of making said dosage form wherein the dosage form has a moisture content of 5% (w / w) or less. The solid dosage form comprises a dried matrix including a first excipient and 0.01 to 50% (w / w) or more than 50% and up to 80% (w / w) of a therapeutic peptide; and one or more additional excipients and at least 5% (w / w) of CMC, based on the total weight of the solid dosage form, wherein the dosage form has a width of 0.5 mm to 2 mm.

The present invention relates to co-treated excipient compositions for solid dose pharmaceutical formulations. In addition, the present invention relates to a process for preparing the co-treated excipient composition and a solid dose pharmaceutical formulation containing the co-treated excipient composition.

Provided herein are compositions and methods relating to solid dosage forms comprising an absorption enhancer. The composition enhances mucosal penetration and absorption of the active ingredient.

The invention provides a rotary die mold process for manufacturing softgel capsules incorporating another solid form within said capsule and wherein said softgel capsule is free of air bubbles, in which at least two material strips are brought together by means of counter-running forming rolls and formed into capsules, a liquid and solid filling material being introduced via a filling wedge segment comprising two concave wedge surfaces; a filling medicine inlet; a fill medicine outlet; an output of solids and pre-fill medicine; a solids feed channel and pre-fill medicine; a pre-filling medicine inlet and a solids inlet. A softgel capsule free of air bubbles having incorporated within said capsule a second solid form, said second solid form being the form of a tablet.

The present disclosure relates to Compound 1 as well as crystalline solid forms and solid dosage forms thereof. The present disclosure also provides methods of making and using the crystalline solid forms of Compound 1, as well as solid dosage forms thereof. # imgabs0 # (compound 1)

The present disclosure relates to a crystalline solid form of Compound 1. The present disclosure also provides a method for preparing the crystalline solid form of Compound 1. In a first aspect, the present disclosure provides a crystalline form of Compound 1, wherein the crystalline form is Crystal Form C, and Form C is characterized by an XRPD pattern comprising peaks at 12.0 ± 0.2, 15.1 ± 0.2, and 21.3 ± 0.2 degrees 2θ. In a second aspect, the present disclosure provides a solid dosage form comprising Crystal Form C of Compound 1 disclosed herein and at least one pharmaceutically acceptable carrier. JPEG2025523826000018.jpg3067

A sieve guide assembly and a method of fractionation using a sieve guide assembly comprising a circular sieve screen (190) and a sieve guide 310 mountable in a fractionating device for fractionating granules for solid dosage forms, such as tablets, capsules or sachets, wherein the fractionating device comprises a drive adapted for: (i) in combination with a sieve screen without a sieve guide, inducing a lateral flow of granules defining lateral streamlines 31a.1. 31b.1, 31c.1, 31d.1 and an orbital flow defining orbital streamlines 31a.2. 31b.2, 31c.2, 31d.2, 31d.3 on the sieve screen (190), and (ii) in combination with the sieve guide assembly, inducing a guided lateral flow of granules defining guided lateral streamlines (331.3) and a central guided orbital flow defining central orbital streamlines (331.2) on the sieve screen (190), whereby the sieve guide assembly is adapted to provide a uniform, controlled and effective exposure of the granules to the sieve screen.

The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.

The present disclosure relates to solid dose formulations for needle-free delivery comprising 0.01 to 60 (w / w) of one or more therapeutic agent and / or prophylactic agent; and 40.0% to 99.99% (w / w) of dextran. The invention further concerns methods of producing a solid dose formulation tablet and application its particular medical uses, in particular as a vaccine.

A device for dispensing a solid dosage form (e.g., a drug or medicament) comprises a receptacle for containing a plurality of units of the solid dosage form, means for vibrating the units of solid dosage form within the receptacle and dispensing means for dispensing the solid dosage form from the receptacle.

The present invention relates to the use of co-processed excipients in continuous manufacturing of solid dosage forms.